



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Please select the member's indication for treatment with Corticotropin:

- Checkboxes for various medical conditions: Allergic States, Collagen Diseases, Dermatologic Diseases, Infantile spasms, Multiple Sclerosis, Nephrotic Syndrome, Rheumatic Disorders, Ophthalmic Diseases, Respiratory Diseases.

Q2. Does the patient have any of the following contraindications: (scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins of porcine origin, or administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of corticotropin injection gel)?

- Yes No

Q3. For infantile spasms, does the patient have a diagnosis of infantile spasms? Please provide clinical documentation to support this diagnosis.

- Yes No

Q4. For infantile spasms, is the patient less than 2 years of age?

- Yes No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party.



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q5. For infantile spasms, is the prescriber a neurologist or in consultation with a neurologist?
Yes No

Q6. For infantile spasms, does the patient have a suspected congenital infection?
Yes No

Q7. For infantile spasms, is corticotropin injection gel going to be used as monotherapy?
Yes No

Q8. For infantile spasms, is corticotropin injection gel going to be dosed in accordance with the recommended dosage regimen per the prescribing information as follows: Initial dose: 150 U/m2 (divided into twice daily intramuscular injections of 75 U/m2) for 2 weeks. Dosing should then be gradually tapered over a 2-week period to avoid adrenal insufficiency. The following is one suggested tapering schedule: 30 U/m2 intramuscularly in the morning for 3 days; 15 U/m2 intramuscularly in the morning for 3 days; 10 U/m2 intramuscularly in the morning for 3 days; and 10 U/m2 every other morning for 6 days? Skip to 77.
Yes No

Q9. For acute exacerbation(s) of Multiple Sclerosis, does the patient demonstrate exacerbation symptoms of multiple sclerosis (including severe weakness, severe loss of vision, severe coordination problems, or severe walking impairment)? Please provide clinical documentation to support exacerbation symptoms of multiple sclerosis.
Yes No

Q10. For acute exacerbation(s) of Multiple Sclerosis, is the patient 18 years or older?
Yes No

Q11. For acute exacerbation(s) of Multiple Sclerosis, is the prescriber a neurologist or in consultation with a neurologist?
Yes No

Q12. For acute exacerbation(s) of Multiple Sclerosis, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?
A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
Yes No

Q13. For acute exacerbation(s) of Multiple Sclerosis, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records or sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.
A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
Yes No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q14. For acute exacerbation(s) of Multiple Sclerosis, is documentation attached that the patient is currently being treated with a disease modifying drug for multiple sclerosis (such as Avonex, Dimethyl Fumarate DR, Glatiramer Acetate, , Aubagio)? Please note these medications require prior authorization.

Yes No

Q15. For acute exacerbation(s) of Multiple Sclerosis, is corticotropin injection gel being used to treat an acute exacerbation of Multiple Sclerosis and therefore is not being used as "pulse therapy" (defined as use on a once monthly or routine basis to prevent MS exacerbations)? Skip to 77.

Yes No

Q16. For Nephrotic Syndrome, is corticotropin injection gel being used to induce diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythematosus? Please provide clinical documentation to support this diagnosis.

Yes No

Q17. For Nephrotic Syndrome, is the patient over 2 years of age? I

Yes No

Q18. For Nephrotic Syndrome, is the prescriber a nephrologist or in consultation with a nephrologist?

Yes No

Q19. For Nephrotic Syndrome, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications? Treatment with the following agents should be dictated by the type of renal pathology causing nephrotic syndrome.

- A) Angiotension-converting enzyme inhibitors (such as lisinopril, benazepril, captopril)
B) Angiotension receptor blockers (such as valsartan, irbesartan, losartan)
C) Loop diuretics (such as furosemide, bumetanide)
D) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
E) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
F) Alkylating agents (such as cyclophosphamide)
G) Immunosuppressive Agents (such as cyclosporine, tacrolimus, mycophenolate)

Yes No

Q20. For Nephrotic Syndrome, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records or sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Angiotension-converting enzyme inhibitors (such as lisinopril, benazepril, captopril)
B) Angiotension receptor blockers (such as valsartan, irbesartan, losartan)
C) Loop diuretics (such as furosemide, bumetanide)
D) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
E) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
F) Alkylating agents (such as cyclophosphamide)



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

G) Immunosuppressive Agents (such as cyclosporine, tacrolimus, mycophenolate)

Yes No

Q21. For Nephrotic Syndrome, is documentation of evidence-based clinical literature supporting the use of corticotropin injection gel for this indication attached? Skip to 77.

Yes No

Q22. For Rheumatic Disorders, does the patient have a diagnosis of Psoriatic arthritis, Rheumatoid arthritis, Juvenile rheumatoid arthritis, or Ankylosing spondylitis? Please provide clinical documentation to support this diagnosis.

Yes No

Q23. For Rheumatic Disorders, is the patient over 2 years of age?

Yes No

Q24. For Rheumatic Disorders, is the prescriber a rheumatologist or in consultation with a rheumatologist?

Yes No

Q25. For Rheumatic Disorders, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)

Yes No

Q26. For Rheumatic Disorders, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records or sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)

Yes No

Q27. For Rheumatic Disorders, is the patient currently receiving maintenance treatment for the condition (such as non-biologic DMARDs, TNF inhibitor, or other biologic medication)? Please provide documentation.

Yes No

Q28. For Rheumatic Disorders, is corticotropin injection gel being used as adjunctive therapy for short-term use (to tide the patient over an acute episode or exacerbation) in a rheumatic disorder?

Yes No

Q29. For Rheumatic Disorders, is documentation of evidence-based clinical literature supporting the use of



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

corticotropin injection gel for this indication attached? Skip to 77.

Yes No

Q30. For Collagen Diseases, is the patient over 2 years of age?

Yes No

Q31. For Collagen Diseases, is documentation of evidence-based clinical literature supporting the use of corticotropin injection gel for this indication attached? Skip to 77.

Yes No

Q32. For systemic lupus erythematosus, does the patient have a diagnosis of systemic lupus erythematosus? Please provide clinical documentation to support this diagnosis.

Yes No

Q33. For systemic dermatomyositis, does the patient have a diagnosis of systemic dermatomyositis (polymyositis)? Please provide clinical documentation to support this diagnosis.

Yes No

Q34. 35. For systemic lupus erythematosus, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Non-steroidal anti-inflammatory drugs (such as naproxen, ibuprofen)
D) Antimalarial agents (such as hydroxychloroquine, chloroquine)
E) Immunosuppressive agents (such as azathioprine, methotrexate, mycophenolate, and cyclosporine)
F) Alkylating agents (such as cyclophosphamide)

Yes No

Q35. For systemic lupus erythematosus, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records and sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Non-steroidal anti-inflammatory drugs (such as naproxen, ibuprofen)
D) Antimalarial agents (such as hydroxychloroquine, chloroquine)
E) Immunosuppressive agents (such as azathioprine, methotrexate, mycophenolate, and cyclosporine)
F) Alkylating agents (such as cyclophosphamide)

Yes No

Q36. For systemic dermatomyositis, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

- B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Antimalarial agents (such as hydroxychloroquine)
D) Immunosuppressive agents (such as azathioprine, methotrexate, mycophenolate, cyclosporine)
E) Alkylating agents (such as cyclophosphamide)

Yes No

Q37. For systemic dermatomyositis, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records and sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Antimalarial agents (such as hydroxychloroquine)
D) Immunosuppressive agents (such as azathioprine, methotrexate, mycophenolate, cyclosporine)
E) Alkylating agents (such as cyclophosphamide)

Skip to 77.

Yes No

Q38. For Dermatologic Diseases, is the patient over 2 years of age?

Yes No

Q39. For Dermatologic Diseases, is documentation of evidence-based clinical literature supporting the use of corticotropin injection gel for this indication attached?

Yes No

Q40. For Severe erythema multiforme, does the patient have a diagnosis of severe erythema multiforme? Please provide clinical documentation to support the diagnosis.

Yes No

Q41. For Stevens-Johnson syndrome, does the patient have a diagnosis of Stevens-Johnson syndrome? Please provide clinical documentation to support the diagnosis.

Yes No

Q42. For Severe erythema multiforme, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Antiviral agents (such as acyclovir, valacyclovir, famciclovir)
D) Immunosuppressive agents (such as azathioprine, mycophenolate, dapsone, cyclosporine)
E) Antimalarial agents (such as hydroxychloroquine)

Yes No

Q43. For Severe erythema multiforme, is documentation of trial(s) with the following formulary therapeutic classes or

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

medications, dates, and outcomes, such as medical or pharmacy records and sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Antiviral agents (such as acyclovir, valacyclovir, famciclovir)
D) Immunosuppressive agents (such as azathioprine, mycophenolate, dapsone, cyclosporine)
E) Antimalarial agents (such as hydroxychloroquine)

Skip to 77.

Yes No

Q44. For Stevens-Johnson syndrome, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Immunosuppressive agents (such as cyclosporine)

Yes No

Q45. For Stevens-Johnson syndrome, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records and sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Immunosuppressive agents (such as cyclosporine)

Yes No

Q46. For serum sickness, does the patient have a diagnosis of serum sickness? Please provide clinical documentation to support this diagnosis.

Yes No

Q47. For serum sickness, Is the patient over 2 years of age?

Yes No

Q48. For serum sickness, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Antihistamines (such as hydroxyzine, cetirizine, loratadine, fexofenadine)
D) Non-steroidal anti-inflammatory drugs (such as naproxen, ibuprofen)

Yes No

Q49. For serum sickness, is documentation of trial(s) with the following formulary therapeutic classes or medications,



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

dates, and outcomes, such as medical or pharmacy records and sample logs, attached? Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Intravenous corticosteroids (such as methylprednisolone, dexamethasone)
B) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
C) Antihistamines (such as hydroxyzine, cetirizine, loratadine, fexofenadine)
D) Non-steroidal anti-inflammatory drugs (such as naproxen, ibuprofen)

Yes No

Q50. For serum sickness, is documentation of evidence-based clinical literature supporting the use of corticotropin injection gel for this indication attached? Skip to 77.

Yes No

Q51. For Ophthalmic Diseases, is the patient over 2 years of age?

Yes No

Q52. For Ophthalmic Diseases, is the prescriber an ophthalmologist or in consultation with an ophthalmologist?

Yes No

Q53. For Ophthalmic Diseases, is documentation of evidence-based clinical literature supporting the use of corticotropin injection gel for this indication attached?

Yes No

Q54. For optic neuritis, does the patient have a diagnosis of optic neuritis? Please provide clinical documentation to support this diagnosis.

Yes No

Q55. For keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, chorioretinitis; or anterior segment inflammation, does the patient have a diagnosis of keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, chorioretinitis; or anterior segment inflammation? Please provide clinical documentation to support the diagnosis.

Yes No

Q56. For optic neuritis, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Intravenous corticosteroids (such as methylprednisolone)
B) Oral corticosteroids (such as methylprednisolone)
C) Immunomodulatory agents (such as Avonex, Glatiramer Acetate) Please note Avonex, Glatiramer Acetate require prior authorization.

Yes No

Q57. For optic neuritis, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records and sample logs, attached? Please attach documentation



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:
Prescriber Name:

of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Intravenous corticosteroids (such as methylprednisolone)
B) Oral corticosteroids (such as methylprednisolone)
C) Immunomodulatory agents (such as Avonex, Glatiramer Acetate). Please note Avonex, Glatiramer Acetate require prior authorization.

**These agents are for patients with optic neuritis and abnormal brain MRIs considered to have a clinically isolated syndrome suggestive of Multiple Sclerosis. **

Yes No

Q58. For keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, chorioretinitis; or anterior segment inflammation, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?

- A) Ophthalmic corticosteroids (such as dexamethasone, prednisolone)
B) Intravenous corticosteroids (such as methylprednisolone)
C) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
D) Calcineurin inhibitor (cyclosporine, tacrolimus)
E) Immunosuppressive agents (such as azathioprine, methotrexate, mycophenolate)
F) Alkylating agents (such as cyclophosphamide)

Yes No

Q59. For keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, chorioretinitis; or anterior segment inflammation, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records and sample logs, attached?

Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.

- A) Ophthalmic corticosteroids (such as dexamethasone, prednisolone)
B) Intravenous corticosteroids (such as methylprednisolone)
C) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
D) Calcineurin inhibitor (cyclosporine, tacrolimus)
E) Immunosuppressive agents (such as azathioprine, methotrexate, mycophenolate)
F) Alkylating agents (such as cyclophosphamide)

Skip to 77.

Yes No

Q60. For sarcoidosis, does the patient have a diagnosis of sarcoidosis? Please provide clinical documentation to support this diagnosis.

Yes No

Q61. For sarcoidosis, is the patient over 2 years of age?

Yes No

Q62. For sarcoidosis, has the patient tried and failed, or has a contraindication or intolerance to the following formulary therapeutic classes or medications?



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

- A) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
B) Topical corticosteroids (such as clobetasol,)
C) Inhaled corticosteroids (such as budesonide, Flovent Diskus, Flovent HFA)
D) Immunosuppressive agents (such as azathioprine, methotrexate, leflunomide)
E) Antimalarial agents (such as hydroxychloroquine, chloroquine)

Yes No

Q63. For sarcoidosis, is documentation of trial(s) with the following formulary therapeutic classes or medications, dates, and outcomes, such as medical or pharmacy records and sample logs, attached? (Please attach documentation of why these formulary alternatives cannot be used and/or documentation (including dose, dates/duration of use, and specific outcomes) showing previous use of these formulary alternatives.)

- A) Oral corticosteroids (such as prednisone, methylprednisolone, dexamethasone)
B) Topical corticosteroids (such as clobetasol, halobetasol)
C) Inhaled corticosteroids (such as budesonide, Flovent Diskus, Flovent HFA)
D) Immunosuppressive agents (such as azathioprine, methotrexate, leflunomide)
E) Antimalarial agents (such as hydroxychloroquine, chloroquine)

Yes No

Q64. For sarcoidosis, is documentation of evidence-based clinical literature supporting the use of corticotropin injection gel Gel for this indication attached? Skip to 77.

Yes No

Q65. Renewal: For infantile spasms, is the patient less than 2 years of age?

Yes No

Q66. Renewal: For infantile spasms, does the patient have a suspected congenital infection?

Yes No

Q67. Renewal: For infantile spasms, is corticotropin injection gel going to be used as monotherapy?

Yes No

Q68. Renewal: For acute exacerbation(s) of Multiple Sclerosis, is documentation attached that the patient is currently being treated with a disease modifying drug for multiple sclerosis (such as Dimethyl Fumarate DR, Glatiramer Acetate, Aubagio)? Please note these medications require prior authorization.

Yes No

Q69. Renewal: For acute exacerbation(s) of Multiple Sclerosis, is corticotropin injection gel being used to treat an acute exacerbation of Multiple Sclerosis and therefore is not being used as "pulse therapy" (defined as use on a once monthly or routine basis to prevent MS exacerbations)?

Yes No

Q70. Renewal: For Rheumatic Disorders, is the patient currently receiving maintenance treatment for the condition



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Corticotropin (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

(such as non-biologic DMARDs, TNF inhibitor, or other biologic medication)? Please provide documentation.

Yes checkbox

No checkbox

Q71. Renewal: Has the patient been previously approved for corticotropin injection gel? If NO, start with question 2.

Yes checkbox

No checkbox

Q72. Renewal: Has the patient been compliant with taking corticotropin injection gel?

Yes checkbox

No checkbox

Q73. Renewal: Has the patient been tolerating corticotropin injection gel without any significant side effects?

Yes checkbox

No checkbox

Q74. Renewal: Has the patient experienced resolution of symptoms/clinical improvement while receiving corticotropin injection gel treatment? Please attach supporting documentation showing the response to prior treatment.

Yes checkbox

No checkbox

Q75. Renewal: Does the patient have any of the following contraindications: (scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins of porcine origin, or administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of corticotropin injection gel)?

Yes checkbox

No checkbox

Q76. Renewal: Does the patient require treatment beyond the initial approved duration? Please attach progress notes demonstrating the need for continued treatment along with the planned taper schedule.

Yes checkbox

No checkbox

Q77. Additional Information:

Prescriber Signature

Date

Updated for 2023